List_of_withdrawn_drugs

List of withdrawn drugs

List of withdrawn drugs

Add article description

Drugs or medicines may be withdrawn from commercial markets because of risks to patients, but also because of commercial reasons (e.g. lack of demand and relatively high production costs). Where risks or harms is the reason for withdrawal, this will usually have been prompted by unexpected adverse effects that were not detected during Phase III clinical trials, i.e. they were only made apparent from postmarketing surveillance data collected from the wider community over longer periods of time.

This list is not limited to drugs that were ever approved by the FDA. Some of them (lumiracoxib, rimonabant, tolrestat, ximelagatran and ximelidine, for example) were approved to be marketed in Europe but had not yet been approved for marketing in the US, when side effects became clear and their developers pulled them from the market. Some drugs in this list (e.g. LSD) were never approved for marketing in the US or Europe.

Significant withdrawals

More information Drug name, Withdrawn ...

Withdrawn clinical trial drugs

See also

References

  1. [1]
    Branch, Government of Canada, Health Canada, Public Affairs, Consultation and Communications. "Health Canada – Home Page". Archived from the original on 28 June 2005. Retrieved 28 November 2016.{{cite web}}: CS1 maint: multiple names: authors list (link)
  2. [2]
    Qureshi, ZP; Seoane-Vazquez, E; Rodriguez-Monguio, R; Stevenson, KB; Szeinbach, SL (July 2011). "Market withdrawal of new molecular entities approved in the United States from 1980 to 2009". Pharmacoepidemiology and Drug Safety. 20 (7): 772–7. doi:10.1002/pds.2155. PMID 21574210. S2CID 23821961.
  3. [3]
    Fung, M.; Thornton, A.; Mybeck, K.; Wu, J. H.-h.; Hornbuckle, K.; Muniz, E. (1 January 2001). "Evaluation of the Characteristics of Safety Withdrawal of Prescription Drugs from Worldwide Pharmaceutical Markets-1960 to 1999". Therapeutic Innovation & Regulatory Science. 35 (1): 293–317. doi:10.1177/009286150103500134. S2CID 73036562.
  4. [4]
    "WHO Drug Information Vol. 8, No. 2, 1994, page 64" (PDF). Archived from the original (PDF) on 3 March 2012. Retrieved 28 November 2016.
  5. [5]
    Berson, A; et al. (2001). "Toxicity of alpidem, a peripheral benzodiazepine receptor ligand, but not zolpidem, in rat hepatocytes: role of mitochondrial permeability transition and metabolic activation" (PDF). J Pharmacol Exp Ther. 299 (2): 793–800. PMID 11602696.
  6. [6]
    Grady, Denise (2002-06-08). "U.S. Lets Drug Tied to Deaths Back on Market". The New York Times. ISSN 0362-4331. Retrieved 2021-07-20.
  7. [7]
    DrugBank. "Amineptine". Archived from the original on 27 September 2013. Retrieved 24 September 2013.
  8. [8]
    "Determination That Ardeparin Sodium Injection Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness". Federal Register. 2002-05-23. Retrieved 2021-07-20.
  9. [9]
    "FDA Response to Citizen Request re Ardeparin". fda.gov. Archived from the original on 18 January 2017. Retrieved 28 April 2018.
  10. [10]
    DrugBank. "Bezitramide". Archived from the original on 27 September 2013. Retrieved 24 September 2013.
  11. [11]
    DrugBank. "Bunamiodyl". Archived from the original on 27 September 2013. Retrieved 24 September 2013.
  12. [12]
    WHO. Consolidated List of Products – Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or Not Approved by Governments, Twelfth Issue – Pharmaceuticals Archived 2014-11-09 at Wikiwix. United Nations – New York, 2005
  13. [13]
    Department of Economic and Social Affairs of the United Nations Secretariat Consolidated List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or not Approved by Governments Twelfth Issue: Pharmaceuticals Archived 2012-10-23 at the Wayback Machine United Nations – New York, 2005
  14. [14]
    Schubert-Zsilavecz, Manfred (2011). "Arzneimittelrücknahmen Rückrufe im Rückblick". Pharmazeutische Zeitung (German). Archived from the original on 27 September 2013. Retrieved 25 September 2013.
  15. [15]
    DrugBank. "Dantron". Archived from the original on 27 September 2013. Retrieved 24 September 2013.
  16. [16]
    "Press Announcements – Xanodyne agrees to withdraw propoxyphene from the U.S. market". Food and Drug Administration. Archived from the original on 13 November 2016. Retrieved 28 November 2016.
  17. [17]
    Col John Lammie et al. Report of the Department Of Defense: 1,3 Dimethylamylamine (Dmaa) Safety Review Panel Archived 2014-01-19 at the Wayback Machine June 3, 2013
  18. [18]
    FDA. "Stimulant Potentially Dangerous to Health, FDA Warns". Food and Drug Administration. Archived from the original on 1 February 2014. Retrieved 26 January 2014.
  19. [19]
    Drotrecogin Alfa (Activated) in Adults with Septic Shock Archived 2015-09-29 at the Wayback Machine, N Engl J Med 2012; 366:2055–2064, May 31, 2012, doi:10.1056/NEJMoa1202290
  20. [20]
    "Xigris (drotrecogin alfa (activated)) to be withdrawn due to lack of efficacy". Press release. London, UK: European Medicines Agency. 25 October 2011. Archived from the original on 28 October 2011. Retrieved 26 October 2011.
  21. [21]
    Armstrong, Drew (25 October 2011). "Lilly Pulls Xigris Off Markets After Sepsis Drug Fails Study". Bloomberg Businessweek. Archived from the original on 2011-10-29. Retrieved 2011-10-25.
  22. [22]
    DrugBank. "Ethyl carbamate". Archived from the original on 27 September 2013. Retrieved 24 September 2013.
  23. [23]
    DrugBank. "Fenfluramine". Archived from the original on 27 September 2013. Retrieved 24 September 2013.
  24. [24]
    "Withdrawal of pain medicine flupirtine endorsed". Retrieved 13 July 2018.
  25. [25]
    FDA. "FDA approves Mylotarg for treatment of acute myeloid leukemia". Food and Drug Administration. Retrieved 17 February 2020.
  26. [26]
    European medicines Agency. "EMA suspends Picato as a precaution while review of skin cancer risk continues" (PDF).
  27. [27]
    "Ingenol mebutate gel (Picato▼): Increased incidence of skin tumours seen in some clinical studies".
  28. [28]
    DrugBank. "Iproniazid". Archived from the original on 27 September 2013. Retrieved 24 September 2013.
  29. [29]
    Centers for Disease Control and Prevention (CDC) (December 2009). "Agranulocytosis associated with cocaine use – four States, March 2008 – November 2009". Morb. Mortal. Wkly. Rep. 58 (49): 1381–5. PMID 20019655. Archived from the original on 2017-06-25.
  30. [30]
    Nancy Y Zhu; Donald F. LeGatt; A Robert Turner (February 2009). "Agranulocytosis After Consumption of Cocaine Adulterated With Levamisole". Annals of Internal Medicine. 150 (4): 287–289. doi:10.7326/0003-4819-150-4-200902170-00102. PMID 19153405.
  31. [31]
    Kinzie, Erik (April 2009). "Levamisole Found in Patients Using Cocaine". Annals of Emergency Medicine. 53 (4): 546–7. doi:10.1016/j.annemergmed.2008.10.017. PMID 19303517. Archived from the original on 2015-12-24. Retrieved 2009-08-18.
  32. [32]
    FDA (13 February 2020). "FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market". FDA. Retrieved 17 February 2020.
  33. [33]
    Central Drugs Standard Control Organization. "Drugs Banned In India". Ministry of Health and Family Welfare, Government of India. Archived from the original on 21 February 2015. Retrieved 24 September 2013.
  34. [34]
    "Drug Effects – Methaqualone". South African Police Service. Archived from the original on 29 August 2003. Retrieved 24 September 2013.
  35. [35]
    Cosgrove-Mather, Bootie (December 5, 2007). "Anti-Depressant Taken Off Market". CBS NEWS. Archived from the original on 2 October 2013. Retrieved 29 September 2013.
  36. [36]
    Babai, S; Auclert, L; Le-Louët, H (November 2021). "Safety data and withdrawal of hepatotoxic drugs". Therapie. 76 (6): 715–723. doi:10.1016/j.therap.2018.02.004. PMID 29609830.
  37. [37]
    Lexchin, Joel (15 March 2005). "Drug withdrawals from the Canadian market for safety reasons, 1963–2004". CMAJ. pp. 765–767. doi:10.1503/cmaj.045021. Retrieved 29 October 2023.
  38. [38]
    DrugBank. "Oxeladin". Archived from the original on 27 September 2013. Retrieved 24 September 2013.
  39. [39]
    DrugBank. "Oxyphenbutazone". Archived from the original on 27 September 2013. Retrieved 24 September 2013.
  40. [40]
    Biron, P (15 May 1986). "Withdrawal of oxyphenbutazone: what about phenylbutazone?". CMAJ: Canadian Medical Association Journal. 134 (10): 1119–20. PMC 1491052. PMID 3697857.
  41. [41]
    DrugBank. "Pemoline". Archived from the original on 27 September 2013. Retrieved 24 September 2013.
  42. [42]
    DrugBank. "Phenacetin". Archived from the original on 27 September 2013. Retrieved 24 September 2013.
  43. [43]
    Wysowski, Diane K.; Swartz, L (2005). "Adverse Drug Event Surveillance and Drug Withdrawals in the United States, 1969–2002: The Importance of Reporting Suspected Reactions". Archives of Internal Medicine. 165 (12): 1363–9. doi:10.1001/archinte.165.12.1363. PMID 15983284.
  44. [44]
    Commissioner, Office of the. "Safety Alerts for Human Medical Products – Phenylpropanolamine hydrochloride (PPA)". Food and Drug Administration. Archived from the original on 23 October 2016. Retrieved 28 November 2016.
  45. [45]
    DrugBank. "Phenylpropanolamine". Archived from the original on 27 September 2013. Retrieved 24 September 2013.
  46. [46]
    DrugBank. "Prenylamine". Archived from the original on 27 September 2013. Retrieved 24 September 2013.
  47. [47]
    "Withdrawal of Rotavirus Vaccine Recommendation". www.cdc.gov.
  48. [48]
    DrugBank. "Sertindole". Archived from the original on 27 September 2013. Retrieved 24 September 2013.
  49. [49]
    "Sibutramine (brand name Reductil) Information – Australia". Abbott Laboratories. 2010. Archived from the original on 2010-10-14. Retrieved 2010-10-08.
  50. [50]
    Health Canada Endorsed Important Safety Information on MERIDIA (Sibutramine Hydrochloride Monohydrate) Archived 2013-01-11 at the Wayback Machine: Subject: Voluntary withdrawal of Meridia (sibutramine) capsules from the Canadian market.
  51. [51]
    "Notification of Termination of Production, Sale, and Usage of Sibutramine Preparations and Their Active Pharmaceutical Ingredient". sda.gov in People's Republic of China. October 30, 2010. Archived from the original on October 7, 2011. Retrieved 2011-05-21.
  52. [52]
    (in German) Sibutramin-Vertrieb in der Europäischen Union ausgesetzt . Abbott Laboratories in Germany. Press Release 2010-01-21. Retrieved 2010-01-27
  53. [53]
    "De-registration of pharmaceutical products containing sibutramine" (Press release). info.gov in Hong Kong. November 2, 2010. Archived from the original on October 21, 2011. Retrieved 2010-11-08.
  54. [54]
    "Banned Medicines" (Press release). Ministry of Health and Family Welfare. February 10, 2011. Archived from the original on July 23, 2012. Retrieved 2011-03-15.
  55. [55]
    "Withdrawal of Sibutramine (Reductil) in New Zealand" (Press release). MedSafe in New Zealand. October 11, 2010. Archived from the original on October 14, 2012. Retrieved 2012-11-06.
  56. [56]
    "FDA warns online sellers of banned slimming pills". January 12, 2014. Archived from the original on February 21, 2014. Retrieved February 20, 2014.
  57. [57]
    "Thai FDA reveals voluntary withdrawal of sibutramine from the Thai market" (PDF) (Press release). Food and Drug Administration of Thailand. October 20, 2010. Archived from the original (PDF) on May 11, 2011. Retrieved 2010-12-22.
  58. [58]
    "Top obesity drug sibutramine being suspended". BBC News. 2010-01-22. Archived from the original on 2010-01-25. Retrieved 2010-01-22.
  59. [59]
    Rockoff, Jonathan D.; Dooren, Jennifer Corbett (October 8, 2010). "Abbott Pulls Diet Drug Meridia Off US Shelves". The Wall Street Journal. Archived from the original on 11 October 2010. Retrieved 8 October 2010.
  60. [60]
    H. Gurdon: Japan bans shingles drug after deaths Archived 2003-06-26 at the Wayback Machine BMJ 1994;309:627
  61. [61]
    Paar, W.D; Müller-Jakic. "Ruhen der Zulassung Tetrazepam haltiger Arzneimittel in der EU (German)" (PDF). Sanofi-Aventis Deutschland GmbH. Archived from the original (PDF) on 27 September 2013. Retrieved 25 September 2013.
  62. [62]
    Luippold, Gerd (2006). "Renaissance des Contergan-Wirkstoffs". Pharmazeutische Zeitung (German). Archived from the original on 27 September 2013. Retrieved 25 September 2013.
  63. [63]
    Drugbank. "Thenalidine". Archived from the original on 27 September 2013. Retrieved 24 September 2013.
  64. [64]
    Purhonen, M; Koponen, H; Tiihonen, J; Tanskanen, A (November 2012). "Outcome of patients after market withdrawal of thioridazine: A retrospective analysis in a nationwide cohort". Pharmacoepidemiology and Drug Safety. 21 (11): 1227–1231. doi:10.1002/pds.3346. PMID 22941581. S2CID 19560432.
  65. [65]
    "SHARED CARE PROTOCOL Thioridazine" (PDF). NHS Lothian Joint Formulary. March 2012. Archived from the original (PDF) on 2015-05-18.
  66. [66]
    DrugBank. "Triazolam". Archived from the original on 27 September 2013. Retrieved 24 September 2013.
  67. [67]
    Fagius, J.; Osterman, P. O.; Sidén, A.; Wiholm, B. E. (1985). "Guillain-Barré syndrome following zimeldine treatment". Journal of Neurology, Neurosurgery, and Psychiatry. 48 (1): 65–69. doi:10.1136/jnnp.48.1.65. PMC 1028185. PMID 3156214.
  68. [68]
    Pubchem record Archived 2015-06-10 at the Wayback Machine says "withdrawn in 1983"
  69. [69]
    DrugBank. "Zimelidine". Archived from the original on 27 September 2013. Retrieved 24 September 2013.
  70. [70]
    Sachin Bhagchandani, Jeremiah A.Johnson, and Darrell J.Irvine (2021). "Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants". Advanced Drug Delivery Reviews. 175: 113803. doi:10.1016/j.addr.2021.05.013. PMC 9003539. PMID 34058283.{{cite journal}}: CS1 maint: multiple names: authors list (link)
Share this article:

This article uses material from the Wikipedia article List_of_withdrawn_drugs, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.